Document is current
Any future updates will be listed below
-
Authors
Schultz, Chad R.
Swanson, Matthew A.
Dowling, Thomas C.
Bachmann, André S. https://orcid.org/0000-0002-6510-8560
-
Funding
Funding for this research was provided by:
St. Baldrick's Foundation (591704)
MandarinoFoundationGift
- License Information
-
More Information
Article History
Received: 2 March 2021
Accepted: 30 May 2021
First Online: 15 June 2021
Declarations
:
: ASB is the sole inventor of U.S. patent (US 9,072,778) issued on July 7, 2015 entitled “Treatment Regimen for N-Myc, C-Myc, and L-Myc amplified and overexpressed tumors”. ASB was an oncology consultant for Lodo Therapeutics (New York, NY). No potential conflicts of interest were disclosed by the other authors.
